Evidence map›Paper›PMID 28388673›Full record

Trial reportPloS one2017

Proteolysis of mature HIV-1 p6 Gag protein by the insulin-degrading enzyme (IDE) regulates virus replication in an Env-dependent manner.

Friedrich Hahn, Adrian Schmalen, Christian Setz, Melanie Friedrich, Stefan Schlößer, Julia Kölle, Robert Spranger, Pia Rauch, Kirsten Fraedrich, Tatjana Reif and 5 more

Open access · goldAbstract readRandomized Controlled Trial
In one paragraph

Trial report in PloS one, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.1field-weighted citation impact, top 55% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Targeting Insulin-Degrading Enzyme in Insulin Clearance.International journal of molecular sciences · 2021
    Review
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 4 institutions in 3 countries.

Friedrich HahnInstitute of Virology, Friedrich-Alexander-University Erlangen-Nürnberg, Erlangen, Germany.
Adrian SchmalenInstitute of Virology, Friedrich-Alexander-University Erlangen-Nürnberg, Erlangen, Germany.ORCID http://orcid.org/0000-0003-2462-2675
Christian SetzInstitute of Virology, Friedrich-Alexander-University Erlangen-Nürnberg, Erlangen, Germany.
Melanie FriedrichInstitute of Virology, Friedrich-Alexander-University Erlangen-Nürnberg, Erlangen, Germany.
Stefan SchlößerInstitute of Virology, Friedrich-Alexander-University Erlangen-Nürnberg, Erlangen, Germany.
Julia KölleInstitute of Virology, Friedrich-Alexander-University Erlangen-Nürnberg, Erlangen, Germany.
Robert SprangerInstitute of Virology, Friedrich-Alexander-University Erlangen-Nürnberg, Erlangen, Germany.
Pia RauchInstitute of Virology, Friedrich-Alexander-University Erlangen-Nürnberg, Erlangen, Germany.
Kirsten FraedrichInstitute of Virology, Friedrich-Alexander-University Erlangen-Nürnberg, Erlangen, Germany.ORCID http://orcid.org/0000-0003-4792-4991
Tatjana ReifInstitute of Virology, Friedrich-Alexander-University Erlangen-Nürnberg, Erlangen, Germany.
Julia Karius-FischerInstitute of Virology, Friedrich-Alexander-University Erlangen-Nürnberg, Erlangen, Germany.
Ashok BalasubramanyamTranslational Metabolism Unit, Diabetes Research Center, Division of Diabetes, Endocrinology and Metabolism, Baylor College of Medicine, Houston, Texas, United States of America.
Petra HenkleinInstitute of Biochemistry, Charité Universitätsmedizin-Berlin, Berlin, Germany.
Torgils FossenDepartment of Chemistry and Centre for Pharmacy, University of Bergen, Bergen, Norway.
Ulrich SchubertInstitute of Virology, Friedrich-Alexander-University Erlangen-Nürnberg, Erlangen, Germany.
Friedrich-Alexander-Universität Erlangen-Nürnberg · DEBaylor College of Medicine · USCharité - Universitätsmedizin Berlin · DEUniversity of Bergen · NO

Funding

Viral mechanisms of adipocyte dysfuntion: Role of Vpr.R01DK081553 · NIDDK · BAYLOR COLLEGE OF MEDICINE · PI BALASUBRAMANYAM, ASHOK · 2009 to 2012
$1.9M
NIDDK NIH HHS R01 DK081553
6 · The paper itself

Abstract

There is a significantly higher risk for type II diabetes in HIV-1 carriers, albeit the molecular mechanism for this HIV-related pathology remains enigmatic. The 52 amino acid HIV-1 p6 Gag protein is synthesized as the C-terminal part of the Gag polyprotein Pr55. In this context, p6 promotes virus release by its two late (L-) domains, and facilitates the incorporation of the viral accessory protein Vpr. However, the function of p6 in its mature form, after proteolytic release from Gag, has not been investigated yet. We found that the mature p6 represents the first known viral substrate of the ubiquitously expressed cytosolic metalloendopeptidase insulin-degrading enzyme (IDE). IDE is sufficient and required for degradation of p6, and p6 is approximately 100-fold more efficiently degraded by IDE than its eponymous substrate insulin. This observation appears to be specific for HIV-1, as p6 proteins from HIV-2 and simian immunodeficiency virus, as well as the 51 amino acid p9 from equine infectious anaemia virus were insensitive to IDE degradation. The amount of virus-associated p6, as well as the efficiency of release and maturation of progeny viruses does not depend on the presence of IDE in the host cells, as it was shown by CRISPR/Cas9 edited IDE KO cells. However, HIV-1 mutants harboring IDE-insensitive p6 variants exhibit reduced virus replication capacity, a phenomenon that seems to depend on the presence of an X4-tropic Env. Furthermore, competing for IDE by exogenous insulin or inhibiting IDE by the highly specific inhibitor 6bK, also reduced virus replication. This effect could be specifically attributed to IDE since replication of HIV-1 variants coding for an IDE-insensitive p6 were inert towards IDE-inhibition. Our cumulative data support a model in which removal of p6 during viral entry is important for virus replication, at least in the case of X4 tropic HIV-1.

Indexed as

Virus ReplicationCells, Culturedgag Gene Products, Human Immunodeficiency VirusGene Products, envHeLa CellsHIV-1HumansInsulinInsulysinProteolysisT-Lymphocytesgag Gene Products, Human Immunodeficiency VirusGene Products, envInsulinInsulysinp6 gag protein, Human immunodeficiency virus 1

Identifiers

PMID28388673
PMCPMC5384750
OpenAlexW2604853387

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.